Overview

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Phase:
PHASE2
Details
Lead Sponsor:
Alexion Pharmaceuticals, Inc.